Breaking News

Novo Nordisk Invests $2B to Expand API Manufacturing in Denmark

New facility will create additional production capacity to support future market demand for its late-phase product portfolio.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Novo Nordisk will invest $2 billion starting in 2023 to expand an existing Active Pharmaceutical Ingredient (API) production facility in Hillerød, Denmark to support its future portfolio in serious chronic diseases. The facility will create additional production capacity and increase its ability to meet future market demands for its late-phase product portfolio. Construction is underway and the facility is expected to start producing API by early 2029. The project is expected to create 340 ne...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters